'Major Advance': Sotorasib Benefit Persists in KRAS+ NSCLC

The first-in-class KRAS inhibitor showed durable benefit in some patients, but emergence of early resistance requires new combination therapies, investigators say.
Medscape Medical News

source https://www.medscape.com/viewarticle/972067?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?